Beta Bionics (NASDAQ:BBNX) Research Coverage Started at Leerink Partners

Leerink Partners assumed coverage on shares of Beta Bionics (NASDAQ:BBNX) in a report published on Monday morning, MarketBeat reports. The brokerage issued an outperform rating and a $28.00 price target on the stock.

A number of other analysts have also weighed in on BBNX. LADENBURG THALM/SH SH started coverage on shares of Beta Bionics in a report on Thursday, February 20th. They issued a “neutral” rating and a $20.00 price objective for the company. Robert W. Baird began coverage on Beta Bionics in a research report on Thursday, February 20th. They issued a “neutral” rating and a $20.00 target price for the company. Finally, Baird R W upgraded Beta Bionics to a “hold” rating in a research report on Thursday, February 20th. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $24.83.

Beta Bionics Stock Performance

BBNX stock opened at $19.99 on Monday. Beta Bionics has a fifty-two week low of $18.67 and a fifty-two week high of $24.50.

Insider Buying and Selling at Beta Bionics

In other news, major shareholder Hadley Harbor Aggre Wellington purchased 1,000,000 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were acquired at an average price of $17.00 per share, for a total transaction of $17,000,000.00. Following the completion of the acquisition, the insider now directly owns 3,901,599 shares of the company’s stock, valued at $66,327,183. The trade was a 34.46 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Mike Mensinger purchased 33,350 shares of Beta Bionics stock in a transaction that occurred on Friday, January 31st. The stock was purchased at an average price of $17.00 per share, with a total value of $566,950.00. Following the transaction, the insider now owns 59,019 shares in the company, valued at $1,003,323. This represents a 129.92 % increase in their position. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.